drugset / Trial / NCT00343551

Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.

NCT00343551

Phase 3 Completed 654 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to investigate the efficacy (blood pressure lowering effect) and safety of aliskiren given to hypertensive patients after a missed dose.

Timeline

Start
2006-05
Primary completion
2007-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 300 mg